Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

General Review Article

Current Studies of Aspirin as an Anticancer Agent and Strategies to Strengthen its Therapeutic Application in Cancer

Author(s): Phuong H.L. Tran, Beom-Jin Lee and Thao T.D. Tran*

Volume 27, Issue 18, 2021

Published on: 02 November, 2020

Page: [2209 - 2220] Pages: 12

DOI: 10.2174/1381612826666201102101758

Price: $65

Abstract

Aspirin has emerged as a promising intervention in cancer in the past decade. However, there are existing controversies regarding the anticancer properties of aspirin as its mechanism of action has not been clearly defined. In addition, the risk of bleeding in the gastrointestinal tract from aspirin is another consideration that requires medical and pharmaceutical scientists to work together to develop more potent and safe aspirin therapy in cancer. This review presents the most recent studies of aspirin with regard to its role in cancer prevention and treatment demonstrated by highlighted clinical trials, mechanisms of action as well as approaches to develop aspirin therapy best beneficial to cancer patients. Hence, this review provides readers with an overview of aspirin research in cancer that covers not only the unique features of aspirin, which differentiate aspirin from other non-steroidal anti-inflammatory drugs (NSAIDs), but also strategies that can be used in the development of drug delivery systems carrying aspirin for cancer management. These studies convey optimistic messages on the continuing efforts of the scientist on the way of developing an effective therapy for patients with a low response to current cancer treatments.

Keywords: Aspirin, cancer, mechanism of action, prevention, treatment, drug delivery systems.

« Previous
[1]
Sneader W. The discovery of aspirin: a reappraisal. BMJ 2000; 321(7276): 1591-4.
[http://dx.doi.org/10.1136/bmj.321.7276.1591] [PMID: 11124191]
[2]
Paez Espinosa EV, Murad JP, Khasawneh FT. Aspirin: pharmacology and clinical applications. Thrombosis 2012.
[http://dx.doi.org/10.1155/2012/173124]
[3]
Cadavid AP. Aspirin: the mechanism of action revisited in the context of pregnancy complications. Front Immunol 2017; 8: 261.
[http://dx.doi.org/10.3389/fimmu.2017.00261] [PMID: 28360907]
[4]
Montinari MR, Minelli S, De Caterina R. The first 3500 years of aspirin history from its roots - A concise summary. Vascul Pharmacol 2019; 113: 1-8.
[PMID: 30391545]
[5]
Lanas A, McCarthy D, Voelker M, Brueckner A, Senn S, Baron JA. Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds - gastrointestinal adverse effects: a meta-analysis of randomized clinical trials. Drugs R D 2011; 11(3): 277-88.
[PMID: 21902288]
[6]
Derry S, Wiffen PJ, Moore RA. Aspirin for acute treatment of episodic tension-type headache in adults. Cochrane Database Syst Rev 2017; 1(1): CD011888.
[PMID: 28084009]
[7]
Tóth L, Muszbek L, Komáromi I. Mechanism of the irreversible inhibition of human cyclooxygenase-1 by aspirin as predicted by QM/MM calculations. J Mol Graph Model 2013; 40: 99-109.
[http://dx.doi.org/10.1016/j.jmgm.2012.12.013] [PMID: 23384979]
[8]
Farinelli I, Martelletti P. Aspirin and tension-type headache. J Headache Pain 2007; 8(1): 49-55.
[http://dx.doi.org/10.1007/s10194-006-0357-4] [PMID: 17192817]
[9]
Clària J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA 1995; 92(21): 9475-9.
[http://dx.doi.org/10.1073/pnas.92.21.9475] [PMID: 7568157]
[10]
Chiang N, Bermudez EA, Ridker PM, Hurwitz S, Serhan CN. Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci USA 2004; 101(42): 15178-83.
[http://dx.doi.org/10.1073/pnas.0405445101] [PMID: 15471991]
[11]
Renda G, Zurro M, Romano M, De Caterina R. Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. nonselective COX-2 inhibitors. Br J Clin Pharmacol 2010; 69(3): 303-6.
[http://dx.doi.org/10.1111/j.1365-2125.2009.03579.x] [PMID: 20233202]
[12]
Bouvier S, Cochery-Nouvellon E, Lavigne-Lissalde G, et al. Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood 2014; 123(3): 404-13.
[http://dx.doi.org/10.1182/blood-2013-08-522623] [PMID: 24200687]
[13]
Nascimento-Silva V, Arruda MA, Barja-Fidalgo C, Fierro IM. Aspirin-triggered lipoxin A4 blocks reactive oxygen species generation in endothelial cells: a novel antioxidative mechanism. Thromb Haemost 2007; 97(1): 88-98.
[http://dx.doi.org/10.1160/TH06-06-0315] [PMID: 17200775]
[14]
Gil-Villa AM, Alvarez AM, Velásquez-Berrío M, Rojas-López M, Cadavid JAP. Role of aspirin-triggered lipoxin A4, aspirin, and salicylic acid in the modulation of the oxidative and inflammatory responses induced by plasma from women with pre-eclampsia. Am J Reprod Immunol 2020; 83(2): e13207.
[http://dx.doi.org/10.1111/aji.13207] [PMID: 31696583]
[15]
Kutuk O, Basaga H. Aspirin inhibits TNFalpha- and IL-1-induced NF-kappaB activation and sensitizes HeLa cells to apoptosis. Cytokine 2004; 25(5): 229-37.
[http://dx.doi.org/10.1016/j.cyto.2003.11.007] [PMID: 15036249]
[16]
Zhang P, Wu C, Huang X-H, et al. Aspirin suppresses TNF-α-induced MMP-9 expression via NF-κB and MAPK signaling pathways in RAW264.7 cells. Exp Ther Med 2017; 14(6): 5597-604.
[http://dx.doi.org/10.3892/etm.2017.5252] [PMID: 29285098]
[17]
Alfonso L, Ai G, Spitale RC, Bhat GJ. Molecular targets of aspirin and cancer prevention. Br J Cancer 2014; 111(1): 61-7.
[http://dx.doi.org/10.1038/bjc.2014.271] [PMID: 24874482]
[18]
Lai M-Y, Huang J-A, Liang Z-H, Jiang H-X, Tang G-D. Mechanisms underlying aspirin-mediated growth inhibition and apoptosis induction of cyclooxygenase-2 negative colon cancer cell line SW480. World J Gastroenterol 2008; 14(26): 4227-33.
[http://dx.doi.org/10.3748/wjg.14.4227] [PMID: 18636671]
[19]
Dai X, Yan J, Fu X, et al. Aspirin inhibits cancer metastasis and angiogenesis via targeting heparanase. Clin Cancer Res 2017; 23(20): 6267-78.
[http://dx.doi.org/10.1158/1078-0432.CCR-17-0242] [PMID: 28710312]
[20]
Choi B-H, Chakraborty G, Baek K, Yoon HS. Aspirin-induced Bcl-2 translocation and its phosphorylation in the nucleus trigger apoptosis in breast cancer cells. Exp Mol Med 2013; 45(10): e47-7.
[http://dx.doi.org/10.1038/emm.2013.91] [PMID: 24113271]
[21]
Gelbenegger G, Postula M, Pecen L, et al. Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups. BMC Med 2019; 17(1): 198.
[http://dx.doi.org/10.1186/s12916-019-1428-0] [PMID: 31679516]
[22]
Ittaman SV, VanWormer JJ, Rezkalla SH. The role of aspirin in the prevention of cardiovascular disease. Clin Med Res 2014; 12(3-4): 147-54.
[http://dx.doi.org/10.3121/cmr.2013.1197] [PMID: 24573704]
[23]
Mainous Arch G, Tanner Rebecca J, Shorr Ronald I, Limacher Marian C. Use of aspirin for primary and secondary cardiovascular disease prevention in the United States, 2011–2012. J Am Heart Assoc 2014; 3(4): e000989.
[24]
Marquis-Gravel G, Roe MT, Harrington RA, Muñoz D, Hernandez AF, Jones WS. Revisiting the role of aspirin for the primary prevention of cardiovascular disease. Circulation 2019; 140(13): 1115-24.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.119.040205] [PMID: 31545683]
[25]
Drini M. Peptic ulcer disease and non-steroidal anti-inflammatory drugs. Aust Prescr 2017; 40(3): 91-3.
[http://dx.doi.org/10.18773/austprescr.2017.037] [PMID: 28798512]
[26]
Zhu L-L, Xu L-C, Chen Y, Zhou Q, Zeng S. Poor awareness of preventing aspirin-induced gastrointestinal injury with combined protective medications. World J Gastroenterol 2012; 18(24): 3167-72.
[http://dx.doi.org/10.3748/wjg.v18.i24.3167] [PMID: 22791953]
[27]
Lavie CJ, Howden CW, Scheiman J, Tursi J. Upper gastrointestinal toxicity associated with long-term aspirin therapy: consequences and prevention. Curr Probl Cardiol 2017; 42(5): 146-64.
[http://dx.doi.org/10.1016/j.cpcardiol.2017.01.006] [PMID: 28363584]
[28]
Cao Y, Nishihara R, Wu K, et al. Population-wide impact of long-term use of aspirin and the risk for cancer. JAMA Oncol 2016; 2(6): 762-9.
[http://dx.doi.org/10.1001/jamaoncol.2015.6396] [PMID: 26940135]
[29]
Elwood PC, Morgan G, Pickering JE, et al. Aspirin in the treatment of cancer: reductions in metastatic spread and in mortality: a systematic review and meta-analyses of published studies. PLoS One 2016; 11(4): e0152402.
[http://dx.doi.org/10.1371/journal.pone.0152402] [PMID: 27096951]
[30]
Australia CC. Clinical practice guidelines for the prevention, early detection and management of colorectal cancer https://wiki.cancer.org.au/australia/Guidelines:Colorectal_cancer/Introduction
[31]
Chen J, Stark LA. Aspirin Prevention of Colorectal Cancer: Focus on NF-κB Signalling and the Nucleolus. Biomedicines 2017; 5(3): 43.
[http://dx.doi.org/10.3390/biomedicines5030043] [PMID: 28718829]
[32]
Bosetti C, Rosato V, Gallus S, La Vecchia C, Cuzick J, Thorat MA. Aspirin and prostate cancer prevention aspirin and prostate cancer preventionin prostate cancer prevention. Berlin, Heidelberg: Springer Berlin Heidelberg 2014; pp. 93-100.
[33]
Elwood PC, Pickering JE, Morgan G, et al. Systematic review update of observational studies further supports aspirin role in cancer treatment: Time to share evidence and decision-making with patients? PLoS One 2018; 13(9): e0203957.
[PMID: 30252883]
[34]
Wield AM, Walsh CS, Rimel BJ, Cass I, Karlan BY, Li AJ. Aspirin use correlates with survival in women with clear cell ovarian cancer. Gynecol Oncol Rep 2018; 25: 78-81.
[PMID: 29922710]
[35]
Zhu Y, Cheng Y, Luo R-C, Li A-M. Aspirin for the primary prevention of skin cancer: A meta-analysis. Oncol Lett 2015; 9(3): 1073-80.
[http://dx.doi.org/10.3892/ol.2015.2853] [PMID: 25663859]
[36]
Orrell KA, Cices AD, Guido N, et al. Malignant melanoma associated with chronic once-daily aspirin exposure in males: A large, single-center, urban, US patient population cohort study from the “Research on Adverse Drug events And Report” (RADAR) project. J Am Acad Dermatol 2018; 79(4): 762-4.
[http://dx.doi.org/10.1016/j.jaad.2018.03.031] [PMID: 29601934]
[37]
Nagle CM, Ibiebele TI, DeFazio A, Protani MM, Webb PM. Australian Ovarian Cancer Study Group. Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, acetaminophen and ovarian cancer survival. Cancer Epidemiol 2015; 39(2): 196-9.
[http://dx.doi.org/10.1016/j.canep.2014.12.010] [PMID: 25666512]
[38]
Veitonmäki T, Murtola TJ, Määttänen L, et al. Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial. Br J Cancer 2014; 111(7): 1421-31.
[http://dx.doi.org/10.1038/bjc.2014.381] [PMID: 25010865]
[39]
Brasky TM, Wactawski-Wende J. Low-Dose Aspirin and Pancreatic Cancer Risk—Letter. Cancer Epidemiology Biomarkers &amp. Prevention 2017; 26(7): 1154.
[40]
Langley RE. Clinical evidence for the use of aspirin in the treatment of cancer. Ecancermedicalscience 2013; 7: 297-7.
[PMID: 23589726]
[41]
Dovizio M, Tacconelli S, Sostres C, Ricciotti E, Patrignani P. Mechanistic and pharmacological issues of aspirin as an anticancer agent. Pharmaceuticals (Basel) 2012; 5(12): 1346-71.
[http://dx.doi.org/10.3390/ph5121346] [PMID: 24281340]
[42]
Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 1968; 61(1): 46-52.
[http://dx.doi.org/10.1073/pnas.61.1.46] [PMID: 5246932]
[43]
Gasic GJ, Gasic TB, Murphy S. Anti-metastatic effect of aspirin. Lancet 1972; 2(7783): 932-3.
[http://dx.doi.org/10.1016/S0140-6736(72)92581-0] [PMID: 4116642]
[44]
Rothwell PM, Wilson M, Elwin C-E, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376(9754): 1741-50.
[http://dx.doi.org/10.1016/S0140-6736(10)61543-7] [PMID: 20970847]
[45]
Rothwell PM, Fowkes FGR, Belch JFF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377(9759): 31-41.
[http://dx.doi.org/10.1016/S0140-6736(10)62110-1] [PMID: 21144578]
[46]
Rothwell PM, Price JF, Fowkes FGR, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379(9826): 1602-12.
[http://dx.doi.org/10.1016/S0140-6736(11)61720-0] [PMID: 22440946]
[47]
Bastiaannet E, Sampieri K, Dekkers OM, et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer 2012; 106(9): 1564-70.
[http://dx.doi.org/10.1038/bjc.2012.101] [PMID: 22454078]
[48]
García Rodríguez LA, Soriano-Gabarró M, Bromley S, Lanas A, Cea Soriano L. New use of low-dose aspirin and risk of colorectal cancer by stage at diagnosis: a nested case-control study in UK general practice. BMC Cancer 2017; 17(1): 637-7.
[http://dx.doi.org/10.1186/s12885-017-3594-9] [PMID: 28882113]
[49]
Gray RT, Coleman HG, Hughes C, Murray LJ, Cardwell CR. Low-dose aspirin use and survival in colorectal cancer: results from a population-based cohort study. BMC Cancer 2018; 18(1): 228.
[http://dx.doi.org/10.1186/s12885-018-4142-y] [PMID: 29486728]
[50]
McCowan C, Munro AJ, Donnan PT, Steele RJC. Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. Eur J Cancer 2013; 49(5): 1049-57.
[http://dx.doi.org/10.1016/j.ejca.2012.10.024] [PMID: 23182687]
[51]
Sung JJY, Ho JMW, Chan FCH, Tsoi KKF. Low-dose aspirin can reduce colorectal cancer mortality after surgery: A 10-year follow-up of 13 528 colorectal cancer patients. J Gastroenterol Hepatol 2019; 34(6): 1027-34.
[http://dx.doi.org/10.1111/jgh.14562] [PMID: 30515899]
[52]
Walker AJ, Grainge MJ, Card TR. Aspirin and other non-steroidal anti-inflammatory drug use and colorectal cancer survival: a cohort study. Br J Cancer 2012; 107(9): 1602-7.
[http://dx.doi.org/10.1038/bjc.2012.427] [PMID: 23011483]
[53]
Reimers MS, Bastiaannet E, van Herk-Sukel MPP, et al. Aspirin use after diagnosis improves survival in older adults with colon cancer: a retrospective cohort study. J Am Geriatr Soc 2012; 60(12): 2232-6.
[http://dx.doi.org/10.1111/jgs.12033] [PMID: 23176157]
[54]
Burn J, Gerdes A-M, Macrae F, et al. CAPP2 Investigators. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011; 378(9809): 2081-7.
[http://dx.doi.org/10.1016/S0140-6736(11)61049-0] [PMID: 22036019]
[55]
Burn J, Sheth H, Elliott F, et al. CAPP2 Investigators Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet 2020; 395(10240): 1855-63.
[http://dx.doi.org/10.1016/S0140-6736(20)30366-4] [PMID: 32534647]
[56]
Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol 2010; 28(9): 1467-72.
[http://dx.doi.org/10.1200/JCO.2009.22.7918] [PMID: 20159825]
[57]
Huang TB, Yan Y, Guo ZF, et al. Aspirin use and the risk of prostate cancer: a meta-analysis of 24 epidemiologic studies. Int Urol Nephrol 2014; 46(9): 1715-28.
[http://dx.doi.org/10.1007/s11255-014-0703-4] [PMID: 24687637]
[58]
Jacobs CD, Chun SG, Yan J, et al. Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy. Cancer Biol Ther 2014; 15(6): 699-706.
[http://dx.doi.org/10.4161/cbt.28554] [PMID: 24658086]
[59]
Zhang S, Zhang XQ, Ding XW, et al. Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett’s esophagus: a meta-analysis. Br J Cancer 2014; 110(9): 2378-88.
[http://dx.doi.org/10.1038/bjc.2014.127] [PMID: 24651385]
[60]
Tsoi KKF, Ho JMW, Chan FCH, Sung JJY. Long-term use of low-dose aspirin for cancer prevention: A 10-year population cohort study in Hong Kong. Int J Cancer 2019; 145(1): 267-73.
[http://dx.doi.org/10.1002/ijc.32083] [PMID: 30575949]
[61]
Joharatnam-Hogan N, Cafferty F, Hubner R, et al. Add-Aspirin Trial Management Group. Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. Lancet Gastroenterol Hepatol 2019; 4(11): 854-62.
[http://dx.doi.org/10.1016/S2468-1253(19)30289-4] [PMID: 31477558]
[62]
Hwang IC, Chang J, Kim K, Park SM. Aspirin use and risk of hepatocellular carcinoma in a national cohort study of Korean adults. Sci Rep 2018; 8(1): 4968.
[http://dx.doi.org/10.1038/s41598-018-23343-0] [PMID: 29563592]
[63]
Rothwell PM, Wilson M, Price JF, Belch JFF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012; 379(9826): 1591-601.
[http://dx.doi.org/10.1016/S0140-6736(12)60209-8] [PMID: 22440947]
[64]
Coyle C, Cafferty FH, Rowley S, et al. Add-Aspirin investigators. ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Contemp Clin Trials 2016; 51: 56-64.
[http://dx.doi.org/10.1016/j.cct.2016.10.004] [PMID: 27777129]
[65]
Langley R E, Wilson R H, Cafferty F H, et al. Aspirin as adjuvant treatment for colorectal cancer: Rationale and progress of the Add- Aspirin trial. Journal of Clinical Oncology 2019; 37(15_suppl): 3624-4.
[66]
NCT01038583. Aspirin in Reducing Events in the Elderly (ASPREE). ClinicalTrialsgov https://clinicaltrials.gov/ct2/show/NCT01038583
[67]
Mekaj YH, Daci FT, Mekaj AY. New insights into the mechanisms of action of aspirin and its use in the prevention and treatment of arterial and venous thromboembolism. Ther Clin Risk Manag 2015; 11: 1449-56.
[http://dx.doi.org/10.2147/TCRM.S92222] [PMID: 26445544]
[68]
Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol 2012; 9(5): 259-67.
[http://dx.doi.org/10.1038/nrclinonc.2011.199] [PMID: 22473097]
[69]
Wong RSY. Role of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in cancer prevention and cancer promotion. Adv Pharmacol Pharma Sci 2019; p. 20193418975.
[http://dx.doi.org/10.1155/2019/3418975] [PMID: 30838040]
[70]
Zhang Z, Chen F, Shang L. Advances in antitumor effects of NSAIDs. Cancer Manag Res 2018; 10: 4631-40.
[http://dx.doi.org/10.2147/CMAR.S175212] [PMID: 30410398]
[71]
Gilligan MM, Gartung A, Sulciner ML, et al. Aspirin-triggered proresolving mediators stimulate resolution in cancer. Proc Natl Acad Sci USA 2019; 116(13): 6292-7.
[http://dx.doi.org/10.1073/pnas.1804000116] [PMID: 30862734]
[72]
Bonifazi M, Gallus S, Bosetti C, et al. Aspirin use and pancreatic cancer risk. Eur J Cancer Prev 2010; 19(5): 352-4.
[http://dx.doi.org/10.1097/CEJ.0b013e32833b48a4] [PMID: 20502343]
[73]
Ulrych T, Böhm A, Polzin A, et al. Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation. J Thromb Haemost 2011; 9(4): 790-8.
[http://dx.doi.org/10.1111/j.1538-7836.2011.04194.x] [PMID: 21251196]
[74]
Lichtenberger LM, Fang D, Bick RJ, et al. Unlocking aspirin’s chemopreventive activity: role of irreversibly inhibiting platelet cyclooxygenase-1. Cancer Prev Res (Phila) 2017; 10(2): 142-52.
[http://dx.doi.org/10.1158/1940-6207.CAPR-16-0241] [PMID: 27998883]
[75]
Voora D, Rao AK, Jalagadugula GS, et al. Systems pharmacogenomics finds RUNX1 is an aspirin-responsive transcription factor linked to cardiovascular disease and colon cancer. EBioMedicine 2016; 11: 157-64.
[http://dx.doi.org/10.1016/j.ebiom.2016.08.021] [PMID: 27566955]
[76]
Lucotti S, Cerutti C, Soyer M, et al. Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2. J Clin Invest 2019; 129(5): 1845-62.
[http://dx.doi.org/10.1172/JCI121985] [PMID: 30907747]
[77]
Omura N, Griffith M, Vincent A, et al. Cyclooxygenase-deficient pancreatic cancer cells use exogenous sources of prostaglandins. Mol Cancer Res 2010; 8(6): 821-32.
[http://dx.doi.org/10.1158/1541-7786.MCR-09-0336] [PMID: 20530583]
[78]
Colby JK, Klein RD, McArthur MJ, et al. Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. Neoplasia 2008; 10(8): 782-96.
[http://dx.doi.org/10.1593/neo.08330] [PMID: 18670639]
[79]
Pomianowska E, Schjølberg AR, Clausen OPF, Gladhaug IP. COX-2 overexpression in resected pancreatic head adenocarcinomas correlates with favourable prognosis. BMC Cancer 2014; 14(1): 458.
[http://dx.doi.org/10.1186/1471-2407-14-458] [PMID: 24950702]
[80]
Richardsen E, Uglehus RD, Due J, Busch C, Busund L-T. COX-2 is overexpressed in primary prostate cancer with metastatic potential and may predict survival. A comparison study between COX-2, TGF-β, IL-10 and Ki67. Cancer Epidemiol 2010; 34(3): 316-22.
[http://dx.doi.org/10.1016/j.canep.2010.03.019] [PMID: 20409773]
[81]
Ko CJ, Lan SW, Lu YC, et al. Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis. Oncogene 2017; 36(32): 4597-609.
[http://dx.doi.org/10.1038/onc.2017.82] [PMID: 28368394]
[82]
Fujita H, Koshida K, Keller ET, et al. Cyclooxygenase-2 promotes prostate cancer progression. Prostate 2002; 53(3): 232-40.
[http://dx.doi.org/10.1002/pros.10152] [PMID: 12386924]
[83]
Kim HS, Kim T, Kim M-K, Suh DH, Chung HH, Song YS. Cyclooxygenase-1 and -2: molecular targets for cervical neoplasia. J Cancer Prev 2013; 18(2): 123-34.
[http://dx.doi.org/10.15430/JCP.2013.18.2.123] [PMID: 25337538]
[84]
Kulkarni S, Rader JS, Zhang F, et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 2001; 7(2): 429-34.
[PMID: 11234900]
[85]
Li B, Li X, Xiong H, et al. Inhibition of COX2 enhances the chemosensitivity of dichloroacetate in cervical cancer cells. Oncotarget 2017; 8(31): 51748-57.
[http://dx.doi.org/10.18632/oncotarget.18518] [PMID: 28881683]
[86]
Jawanjal P, Salhan S, Dhawan I, et al. Augmented activity of cyclooxygenase-2 in tissue and serum of patients with cervical cancer. J Clin Lab Anal 2016; 30(6): 1198-207.
[http://dx.doi.org/10.1002/jcla.22003] [PMID: 27292107]
[87]
Bocca C, Ievolella M, Autelli R, et al. Expression of Cox-2 in human breast cancer cells as a critical determinant of epithelial-to-mesenchymal transition and invasiveness. Expert Opin Ther Targets 2014; 18(2): 121-35.
[http://dx.doi.org/10.1517/14728222.2014.860447] [PMID: 24325753]
[88]
Harris RE, Casto BC, Harris ZM. Cyclooxygenase-2 and the inflammogenesis of breast cancer. World J Clin Oncol 2014; 5(4): 677-92.
[http://dx.doi.org/10.5306/wjco.v5.i4.677] [PMID: 25302170]
[89]
Hoellen F, Kelling K, Dittmer C, Diedrich K, Friedrich M, Thill M. Impact of cyclooxygenase-2 in breast cancer. Anticancer Res 2011; 31(12): 4359-67.
[PMID: 22199301]
[90]
Wu Y-C, Su L-J, Wang H-W, et al. Co-overexpression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 adversely affects the postoperative survival in non-small cell lung cancer. J Thorac Oncol 2010; 5(8): 1167-74.
[http://dx.doi.org/10.1097/JTO.0b013e3181e2f4f5] [PMID: 20592629]
[91]
Yokouchi H, Kanazawa K, Ishida T, et al. Cyclooxygenase-2 inhibitors for non-small-cell lung cancer: A phase II trial and literature review. Mol Clin Oncol 2014; 2(5): 744-50.
[http://dx.doi.org/10.3892/mco.2014.319] [PMID: 25054040]
[92]
Bergqvist F, Ossipova E, Idborg H, et al. Inhibition of mPGES-1 or COX-2 results in different proteomic and lipidomic profiles in A549 lung cancer cells. Front Pharmacol 2019; 10: 636.
[http://dx.doi.org/10.3389/fphar.2019.00636] [PMID: 31231223]
[93]
Wang D, Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010; 29(6): 781-8.
[http://dx.doi.org/10.1038/onc.2009.421] [PMID: 19946329]
[94]
Roelofs HMJ, Te Morsche RHM, van Heumen BWH, Nagengast FM, Peters WHM. Over-expression of COX-2 mRNA in colorectal cancer. BMC Gastroenterol 2014; 14(1): 1.
[http://dx.doi.org/10.1186/1471-230X-14-1] [PMID: 24383454]
[95]
Liu Y, Sun H, Hu M, et al. The role of cyclooxygenase-2 in colorectal carcinogenesis. Clin Colorectal Cancer 2017; 16(3): 165-72.
[http://dx.doi.org/10.1016/j.clcc.2016.09.012] [PMID: 27810226]
[96]
Hu H, Han T, Zhuo M, et al. Elevated COX-2 expression promotes angiogenesis through EGFR/p38-MAPK/Sp1-dependent signalling in pancreatic cancer. Sci Rep 2017; 7(1): 470-0.
[http://dx.doi.org/10.1038/s41598-017-00288-4] [PMID: 28352075]
[97]
Wang Q, Lu D, Fan L, et al. COX-2 induces apoptosis-resistance in hepatocellular carcinoma cells via the HIF-1α/PKM2 pathway. Int J Mol Med 2018; 43(1): 475-88.
[http://dx.doi.org/10.3892/ijmm.2018.3936]
[98]
Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. Vasc Health Risk Manag 2006; 2(3): 213-9.
[http://dx.doi.org/10.2147/vhrm.2006.2.3.213] [PMID: 17326328]
[99]
Fan Y-J, Zong W-X. The cellular decision between apoptosis and autophagy. Chin J Cancer 2013; 32(3): 121-9.
[PMID: 23114086]
[100]
Wu M, Guan J, Li C, et al. Aberrantly activated Cox-2 and Wnt signaling interact to maintain cancer stem cells in glioblastoma. Oncotarget 2017; 8(47): 82217-30.
[http://dx.doi.org/10.18632/oncotarget.19283] [PMID: 29137258]
[101]
Xia D, Wang D, Kim S-H, Katoh H, DuBois RN. Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nat Med 2012; 18(2): 224-6.
[http://dx.doi.org/10.1038/nm.2608] [PMID: 22270723]
[102]
Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010; 10(3): 181-93.
[http://dx.doi.org/10.1038/nrc2809] [PMID: 20168319]
[103]
Gala MK, Chan AT. Molecular pathways: aspirin and Wnt signaling-a molecularly targeted approach to cancer prevention and treatment. Clin Cancer Res 2015; 21(7): 1543-8.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-0877] [PMID: 25501125]
[104]
Bezawada N, Song M, Wu K, et al. Urinary PGE-M levels are associated with risk of colorectal adenomas and chemopreventive response to anti-inflammatory drugs. Cancer Prev Res (Phila) 2014; 7(7): 758-65.
[http://dx.doi.org/10.1158/1940-6207.CAPR-14-0120] [PMID: 24824037]
[105]
Escate R, Padro T, Borrell-Pages M, et al. Macrophages of genetically characterized familial hypercholesterolaemia patients show up-regulation of LDL-receptor-related proteins. J Cell Mol Med 2017; 21(3): 487-99.
[http://dx.doi.org/10.1111/jcmm.12993] [PMID: 27680891]
[106]
Borrell-Pagès M, Romero JC, Juan-Babot O, Badimon L. Wnt pathway activation, cell migration, and lipid uptake is regulated by low-density lipoprotein receptor-related protein 5 in human macrophages. Eur Heart J 2011; 32(22): 2841-50.
[http://dx.doi.org/10.1093/eurheartj/ehr062] [PMID: 21398644]
[107]
Vallée A, Lecarpentier Y, Vallée J-N. Targeting the canonical WNT/β-catenin pathway in cancer treatment using non-steroidal anti-inflammatory drugs. Cells 2019; 8(7): 726.
[http://dx.doi.org/10.3390/cells8070726] [PMID: 31311204]
[108]
Ma B, Hottiger MO. Crosstalk between Wnt/β-Catenin and NF-κB Signaling Pathway during Inflammation. Front Immunol 2016; 7: 378.
[http://dx.doi.org/10.3389/fimmu.2016.00378] [PMID: 27713747]
[109]
Liao D, Zhong L, Duan T, et al. Aspirin suppresses the growth and metastasis of osteosarcoma through the NF-κB pathway. Clin Cancer Res 2015; 21(23): 5349-59.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-0198] [PMID: 26202947]
[110]
Bashir AIJ, Kankipati CS, Jones S, et al. A novel mechanism for the anticancer activity of aspirin and salicylates. Int J Oncol 2019; 54(4): 1256-70.
[http://dx.doi.org/10.3892/ijo.2019.4701] [PMID: 30720135]
[111]
Deb J, Dibra H, Shan S, et al. Activity of aspirin analogues and vanillin in a human colorectal cancer cell line. Oncol Rep 2011; 26(3): 557-65.
[PMID: 21617874]
[112]
Claudius A-K, Kankipati CS, Kilari RS, et al. Identification of aspirin analogues that repress NF-κB signalling and demonstrate anti-proliferative activity towards colorectal cancer in vitro and in vivo. Oncol Rep 2014; 32(4): 1670-80.
[http://dx.doi.org/10.3892/or.2014.3373] [PMID: 25109257]
[113]
Di Francesco L, López Contreras LA, Sacco A, Patrignani P. New insights into the mechanism of action of aspirin in the prevention of colorectal neoplasia. Curr Pharm Des 2015; 21(35): 5116-26.
[http://dx.doi.org/10.2174/1381612821666150915110706] [PMID: 26369679]
[114]
Dovizio M, Bruno A, Tacconelli S, Patrignani P, Chan AT, Detering E. Mode of Action of Aspirin as a Chemopreventive AgentProspects for Chemoprevention of Colorectal Neoplasia: Emerging Role of Anti-Inflammatory Drugs. Berlin, Heidelberg: Springer Berlin Heidelberg 2013; pp. 39-65.
[http://dx.doi.org/10.1007/978-3-642-30331-9_3]
[115]
Patrignani P, Patrono C. Aspirin and Cancer. J Am Coll Cardiol 2016; 68(9): 967-76.
[http://dx.doi.org/10.1016/j.jacc.2016.05.083] [PMID: 27561771]
[116]
Voelker M, Hammer M. Dissolution and pharmacokinetics of a novel micronized aspirin formulation. Inflammopharmacology 2012; 20(4): 225-31.
[http://dx.doi.org/10.1007/s10787-011-0099-z] [PMID: 22057729]
[117]
Bakar SK, Niazi S. Stability of aspirin in different media. J Pharm Sci 1983; 72(9): 1024-6.
[http://dx.doi.org/10.1002/jps.2600720914] [PMID: 6631686]
[118]
Lanas A, Gargallo CJ. Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective. J Gastroenterol 2015; 50(6): 626-37.
[http://dx.doi.org/10.1007/s00535-015-1038-3] [PMID: 25595209]
[119]
Jirmář R, Widimský P. Enteric-coated aspirin in cardiac patients: Is it less effective than plain aspirin? Cor Vasa 2018; 60(2): e165-8.
[http://dx.doi.org/10.1016/j.crvasa.2017.05.011]
[120]
Song JM, Upadhyaya P, Kassie F. Nitric oxide-donating aspirin (NO-Aspirin) suppresses lung tumorigenesis in vitro and in vivo and these effects are associated with modulation of the EGFR signaling pathway. Carcinogenesis 2018; 39(7): 911-20.
[http://dx.doi.org/10.1093/carcin/bgy049] [PMID: 29982425]
[121]
Pircher J, Fochler F, Czermak T, et al. Hydrogen sulfide-releasing aspirin derivative ACS14 exerts strong antithrombotic effects in vitro and in vivo. Arterioscler Thromb Vasc Biol 2012; 32(12): 2884-91.
[http://dx.doi.org/10.1161/ATVBAHA.112.300627] [PMID: 23023375]
[122]
Mahmoud FAE, Hashem KS, Elkelawy AMMH. The effect of aspirin nanoemulsion on TNFα and iNOS in gastric tissue in comparison with conventional aspirin. Int J Nanomedicine 2015; 10: 5301-8.
[PMID: 26345150]
[123]
Kanthamneni N, Chaudhary A, Wang J, Prabhu S. Nanoparticulate delivery of novel drug combination regimens for the chemoprevention of colon cancer. Int J Oncol 2010; 37(1): 177-85.
[PMID: 20514409]
[124]
Datt A, El-Maazawi I, Larsen SC. Aspirin loading and release from MCM-41 functionalized with aminopropyl groups via co-condensation or postsynthesis modification methods. J Phys Chem C 2012; 116(34): 18358-66.
[http://dx.doi.org/10.1021/jp3063959]
[125]
Tran PHL, Wang T, Yin W, et al. Development of a nanoamorphous exosomal delivery system as an effective biological platform for improved encapsulation of hydrophobic drugs. Int J Pharm 2019; 566: 697-707.
[http://dx.doi.org/10.1016/j.ijpharm.2019.06.028] [PMID: 31207280]
[126]
Tran PHL, Wang T, Yin W, et al. Aspirin-loaded nanoexosomes as cancer therapeutics. Int J Pharm 2019; 572118786.
[http://dx.doi.org/10.1016/j.ijpharm.2019.118786] [PMID: 31669214]
[127]
Thakkar A, Chenreddy S, Wang J, Prabhu S. Ferulic acid combined with aspirin demonstrates chemopreventive potential towards pancreatic cancer when delivered using chitosan-coated solid-lipid nanoparticles. Cell Biosci 2015; 5: 46-6.
[http://dx.doi.org/10.1186/s13578-015-0041-y] [PMID: 26301084]
[128]
Sutaria D, Grandhi BK, Thakkar A, Wang J, Prabhu S. Chemoprevention of pancreatic cancer using solid-lipid nanoparticulate delivery of a novel aspirin, curcumin and sulforaphane drug combination regimen. Int J Oncol 2012; 41(6): 2260-8.
[http://dx.doi.org/10.3892/ijo.2012.1636] [PMID: 23007664]
[129]
Zhou L, Duan X, Zeng S, et al. Codelivery of SH-aspirin and curcumin by mPEG-PLGA nanoparticles enhanced antitumor activity by inducing mitochondrial apoptosis. Int J Nanomedicine 2015; 10: 5205-18.
[http://dx.doi.org/10.2147/IJN.S84326] [PMID: 26316750]
[130]
Hua H, Zhang H, Kong Q, Wang J, Jiang Y. Complex roles of the old drug aspirin in cancer chemoprevention and therapy. Med Res Rev 2019; 39(1): 114-45.
[http://dx.doi.org/10.1002/med.21514] [PMID: 29855050]
[131]
Huang Y, Lichtenberger LM, Taylor M, et al. Antitumor and antiangiogenic effects of aspirin-PC in ovarian cancer. Mol Cancer Ther 2016; 15(12): 2894-904.
[http://dx.doi.org/10.1158/1535-7163.MCT-16-0074] [PMID: 27638860]
[132]
Cryer B, Bhatt DL, Lanza FL, Dong JF, Lichtenberger LM, Marathi UK. Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial. Am J Gastroenterol 2011; 106(2): 272-7.
[http://dx.doi.org/10.1038/ajg.2010.436] [PMID: 21081908]
[133]
Khoo BL, Grenci G, Lim JSY, et al. Low-dose anti-inflammatory combinatorial therapy reduced cancer stem cell formation in patient-derived preclinical models for tumour relapse prevention. Br J Cancer 2019; 120(4): 407-23.
[http://dx.doi.org/10.1038/s41416-018-0301-9] [PMID: 30713340]
[134]
Hamada T, Giannakis M, Ogino S. Aspirin in the era of immunotherapy. Oncotarget 2017; 8(43): 73370-1.
[http://dx.doi.org/10.18632/oncotarget.20877] [PMID: 29088713]
[135]
Hamada T, Cao Y, Qian ZR, et al. aspirin use and colorectal cancer survival according to tumor CD274 (programmed cell death 1 ligand 1) expression status. J Clin Oncol 2017; 35(16): 1836-44.
[http://dx.doi.org/10.1200/JCO.2016.70.7547] [PMID: 28406723]
[136]
Zelenay S, van der Veen AG, Böttcher JP, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 2015; 162(6): 1257-70.
[http://dx.doi.org/10.1016/j.cell.2015.08.015] [PMID: 26343581]
[137]
Wang D, DuBois RN. The role of prostaglandin e(2) in tumor-associated immunosuppression. Trends Mol Med 2016; 22(1): 1-3.
[http://dx.doi.org/10.1016/j.molmed.2015.11.003] [PMID: 26711015]
[138]
Wu AA, Drake V, Huang H-S, Chiu S, Zheng L. Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. OncoImmunology 2015; 4(7): e1016700.
[http://dx.doi.org/10.1080/2162402X.2015.1016700] [PMID: 26140242]
[139]
Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015; 33(17): 1974-82.
[http://dx.doi.org/10.1200/JCO.2014.59.4358] [PMID: 25605845]
[140]
Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366(26): 2455-65.
[http://dx.doi.org/10.1056/NEJMoa1200694] [PMID: 22658128]
[141]
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366(26): 2443-54.
[http://dx.doi.org/10.1056/NEJMoa1200690] [PMID: 22658127]
[142]
Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015; 27(4): 450-61.
[http://dx.doi.org/10.1016/j.ccell.2015.03.001] [PMID: 25858804]
[143]
Bassani-Sternberg M, Digklia A, Huber F, et al. A Phase Ib study of the combination of personalized autologous dendritic cell vaccine, aspirin, and standard of care adjuvant chemotherapy followed by nivolumab for resected pancreatic adenocarcinoma-a proof of antigen discovery feasibility in three patients. Front Immunol 2019; 10: 1832.
[http://dx.doi.org/10.3389/fimmu.2019.01832] [PMID: 31440238]
[144]
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373(1): 23-34.
[http://dx.doi.org/10.1056/NEJMoa1504030] [PMID: 26027431]
[145]
Robert C, Schachter J, Long GV, et al. KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372(26): 2521-32.
[http://dx.doi.org/10.1056/NEJMoa1503093] [PMID: 25891173]
[146]
Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017; 377(14): 1345-56.
[http://dx.doi.org/10.1056/NEJMoa1709684] [PMID: 28889792]
[147]
Callahan MK, Kluger H, Postow MA, et al. Nivolumab plus ipilimumab in patients with advanced melanoma: Updated survival, response, and safety data in a phase I dose-escalation study. J Clin Oncol 2018; 36(4): 391-8.
[http://dx.doi.org/10.1200/JCO.2017.72.2850] [PMID: 29040030]
[148]
Imbert C, Montfort A, Fraisse M, et al. Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1. Nat Commun 2020; 11(1): 437.
[http://dx.doi.org/10.1038/s41467-019-14218-7] [PMID: 31974367]
[149]
Li L, Hu M, Wang T, Chen H, Xu L. Repositioning aspirin to treat lung and breast cancers and overcome acquired resistance to targeted therapy. Front Oncol 2020; 9: 1503-3.
[http://dx.doi.org/10.3389/fonc.2019.01503] [PMID: 31993373]
[150]
Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012; 367(17): 1596-606.
[http://dx.doi.org/10.1056/NEJMoa1207756] [PMID: 23094721]
[151]
Turturro SB, Najor MS, Ruby CE, Cobleigh MA, Abukhdeir AM. Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin. Breast Cancer Res Treat 2016; 156(1): 33-43.
[http://dx.doi.org/10.1007/s10549-016-3729-8] [PMID: 26915040]

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy